<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862535</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-296-1884</org_study_id>
    <nct_id>NCT02862535</nct_id>
  </id_info>
  <brief_title>Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize the safety and tolerability of
      andecaliximab (GS-5745) as monotherapy and in combination with anti-cancer agents in Japanese
      participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal
      junction (GEJ) adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Safety Profile of Andecaliximab</measure>
    <time_frame>Baseline up to the last dose date plus 30 days (maximum: 6 months)</time_frame>
    <description>The overall safety profile of andecaliximab will be assessed as the percentage of participants experiencing treatment-emergent adverse events (AE), abnormal physical examinations, abnormal 12-lead electrocardiograms (ECG), abnormal vital signs, and abnormal clinical laboratory test findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Andecaliximab</measure>
    <time_frame>Predose and 30 (±15) minutes postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of Andecaliximab</measure>
    <time_frame>Predose and 30 (±15) minutes postdose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUC of Andecaliximab</measure>
    <time_frame>Predose and 30 (±15) minutes postdose</time_frame>
    <description>AUC is defined as the concentration of drug over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Positive Anti-Andecaliximab Antibodies</measure>
    <time_frame>Baseline up to the last dose date plus 30 days (maximum: 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Andecaliximab Monotherapy (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 participants will receive andecaliximab 800 mg until disease progression. If 2 or more participants experience dose limiting toxicities (DLT) within the first 28 days, up to 6 additional participants will be enrolled to receive andecaliximab 600 mg. If 2 additional DLTs occur at 600 mg, the study will be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy Andecaliximab and SP (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 participants will receive andecaliximab 800 mg until disease progression in combination with S-1 plus cisplatin (SP) chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice and/or the in-country label). The dose of andecaliximab is based on safety data from cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy Andecaliximab and SOX (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 participants will receive andecaliximab 1200 mg until disease progression in combination with 80 mg/day to 120 mg/day S-1 depending on body surface area (BSA) plus 100mg/m^2 oxaliplatin (SOX) chemotherapy. The dose of andecaliximab is based on safety data from cohort 1 and other ongoing phase 1 studies of andecaliximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy Andecaliximab and Nivolumab (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 participants will receive andecaliximab 800 mg until disease progression in combination with 3 mg/kg nivolumab chemotherapy. The dose of andecliximab is based on safety data from cohort 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andecaliximab</intervention_name>
    <description>Administered via intravenous (IV) infusion every 3 weeks</description>
    <arm_group_label>Andecaliximab Monotherapy (Cohort 1)</arm_group_label>
    <arm_group_label>Combination Therapy Andecaliximab and SP (Cohort 2)</arm_group_label>
    <arm_group_label>Combination Therapy Andecaliximab and SOX (Cohort 3)</arm_group_label>
    <arm_group_label>Combination Therapy Andecaliximab and Nivolumab (Cohort 4)</arm_group_label>
    <other_name>GS-5745</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Administered orally twice daily for the first 14 days of the 21 day cycle</description>
    <arm_group_label>Combination Therapy Andecaliximab and SP (Cohort 2)</arm_group_label>
    <arm_group_label>Combination Therapy Andecaliximab and SOX (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered via IV infusion on Day 8 of every 5 weeks</description>
    <arm_group_label>Combination Therapy Andecaliximab and SP (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered via IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Combination Therapy Andecaliximab and SOX (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Administered via IV infusion every 2 weeks</description>
    <arm_group_label>Combination Therapy Andecaliximab and Nivolumab (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have been born in Japan and must not have lived outside of Japan for a period &gt; 1
             year in the 5 years prior to Day 1

          -  Must be able to trace their maternal and paternal ancestry of parents and grandparents
             as ethnically Japanese

          -  Histologically confirmed inoperable advanced gastric adenocarcinoma (including
             adenocarcinoma of the GEJ) or relapsed gastric adenocarcinoma

          -  Cohorts 1, 2, and 3: Human Epidermal Growth Factor Receptor 2 (HER2)‑negative tumor
             (primary tumor or metastatic lesion)). Enrollment in Cohort 4 is not restricted by
             HER2 status (adults with HER2‑positive, HER2-negative, or unknown HER2 status are
             eligible)

          -  Cohort 1: Prior antitumor therapy or cytotoxic chemotherapy is acceptable. Individuals
             who are not eligible to receive standard treatments should enroll on the study.

          -  Cohorts 2 and 3: Prior antitumor therapy or cytotoxic chemotherapy for metastatic
             disease is not acceptable. Individuals must be chemo-naive in the metastatic setting.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1

          -  Adequate baseline organ function (within 28 days prior to Day 1)

          -  Coagulation: International Normalized Ratio (INR) ≤ 1.5 (unless receiving
             anticoagulation therapy).

          -  For females of childbearing potential, willingness to use a protocol-recommended
             method of contraception from the screening visit throughout the study treatment period
             and for defined periods following the last dose of andecaliximab and/or anti-cancer
             agent(s)

          -  For males of childbearing potential having intercourse with females of childbearing
             potential, willingness to use a protocol-recommended method of contraception from the
             start of andecaliximab, throughout the study treatment period, and for protocol
             defined periods following the last dose of andecaliximab and/or anti-cancer agent(s)

          -  Willingness to comply with scheduled visits, drug administration plan, imaging
             studies, laboratory tests, other study procedures, and study restrictions

          -  In addition to the applicable criteria above, participants in Cohort 4 must meet
             additional inclusion criteria to be eligible for participation in this study:

               -  Measureable gastric or GEJ adenocarcinoma

               -  Must have progressed on at least 1 prior systemic therapy or line of treatment
                  for unresectable/metastatic disease.

               -  Activated partial thromboplastin (aPTT) ≤ 1.5 times the upper limit of normal.

               -  Thyroid function tests should be within normal limits.

        Key Exclusion Criteria:

          -  History or evidence of a clinically significant disorder, condition, or disease that,
             in the opinion of the investigator and medical monitor would pose a risk to
             participant safety or interfere with the study evaluations, procedures, or completion

          -  Pregnant or lactating. Enrollment of lactating females after discontinuation of
             breastfeeding is not acceptable.

          -  Individuals with known central nervous system (CNS) metastases, unless metastases are
             treated and stable and the individual does not require systemic steroids

          -  Radiotherapy within 28 days of Day 1

          -  Myocardial infarction, symptomatic congestive heart failure (New York Heart
             Association Classification &gt; Class II), unstable angina, or serious uncontrolled
             cardiac arrhythmia within the last 6 months of Day 1

          -  History of major surgery within 28 days of Day 1

          -  Serious systemic fungal, bacterial, viral, or other infection that is not controlled
             or requires IV antibiotics

          -  Individuals known to be positive for human immunodeficiency virus (HIV), hepatitis C
             infection (per local standard diagnostic criteria), or acute or chronic hepatitis B
             infection (per local standard diagnostic criteria)

          -  In addition to the applicable criteria above, paricipants in Cohort 4 who meet any of
             the following exclusion criteria will not be enrolled in this study:

               -  Have received only neoadjuvant or adjuvant therapy for gastric adenocarcinoma

               -  Prior treatment with anti-CTLA-4 agents, anti PD-1 or anti-PD-L1 agents,
                  anti-PD-L2 agents, anti-MMP agents, or other immunomodulatory therapies

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

